TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Bluefish Pharmaceuticals AB (publ)
Closing information (x1000 SEK)
Closing information | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
Turnover |
484,778
|
540,097
|
385,500 |
Financial expenses |
29,463
|
41,154
|
15,398 |
Earnings before taxes |
32,576
|
-90,170
|
-18,974 |
EBITDA |
47,569
|
-27,543
|
17,604 |
Total assets |
588,902
|
540,718
|
568,148 |
Current assets |
463,129
|
411,429
|
457,885 |
Current liabilities |
303,608
|
202,590
|
457,003 |
Equity capital |
44,996
|
-41,649
|
88,697 |
- share capital |
21,584
![]() |
21,584
![]() |
21,584 |
Employees (average) |
126
|
128
|
124 |
Financial ratios
Fiscal year | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
Solvency |
7.6%
|
-7.7%
|
15.6% |
Turnover per employee |
3,847
|
4,220
|
3,109 |
Profit as a percentage of turnover |
6.7%
|
-16.7%
|
-4.9% |
Return on assets (ROA) |
10.5%
|
-9.1%
|
-0.6% |
Current ratio |
152.5%
|
203.1%
|
100.2% |
Return on equity (ROE) |
72.4%
|
216.5%
|
-21.4% |
Change turnover |
-55,319
|
154,597
|
-28,918 |
Change turnover % |
-10%
|
40%
|
-7% |
Chg. No. of employees |
-2
|
4
|
-5 |
Chg. No. of employees % |
-2%
|
3%
|
-4% |
Total value of public sale
Fiscal year | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.